Positive Phase 3 SHIELD II Trial Results -D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI
NDA submission expected in Q1 2026
Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity andDiabetes Market
Successful Warrant ExerciseSignificantly Strengthened Balance Sheet with Cash Runway into 2026
Conference Call Scheduled for Today at 8:30 AM ET
PETACH TIKVA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended June 30, 2025.
Recent Corporate Highlights:
Positive Phase 3 Data and Additional Clinical Insights: Reported positive top-line results from the SHIELD II Phase 3 trial of D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections (SSIs). The study showed statistically significant reduction of 38% (p
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Published 2 months ago
Aug 13, 2025 at 11:30 AM
Neutral
Auto